In patients with acromegaly the secretory pattern of GH is often different from that of the normal. Recently, a paradoxical increase in plasma GH in response to intravenous CRF, in addition to that caused by TRH and LHRH, was reported (Pieters et al., 1984a) .
With respect to GRF, GH response is not always the same as in the normal. Decreased response of plasma GH or no response to GRF administered iv is frequently reported, though GH is increased either to the same as, or to a greater extent than the normal in the majority of the acromegalics (Wood et al., 1983 , Shibasaki et al., 1984 , von Werder et al., 1984 , Pieters et al., 1984b , Gelato et al., 1985 , Arosio et al., 1985 . These abnormalities in GH secretion could be due to either a change in the hypothalamic regulatory mechanism (hypothalamic hor-mones and/or amines) for GH secretion, the disappearance of, or aberrant appearance of, receptors for these hypothalamic hormones at the pituitary level, and/or a change in the postreceptor mechanism. In this study secretory responses of GH to GRF and CRF were examined in vitro in pituitary adenomas from acromegalics, and a comparison was made with those obtained in loading tests for GH secretion before operation.
It was the purpose of this study to determine to what extent GH secretion in vitro can reflect secretion in vivo, and to get further insight into the mechanism underlying abnormal GH secretion in acromegalic patients.
Materials
and Methods
Patients
Eight patients (aged 37-60 yr) with active acromegaly were examined in this study. All these patients had clinical features characteristic of acromegaly, viz, elevated plasma GH and somatomedin-C, or lack of GH suppression after oral administration of 100g glucose. The clinical and biochemical data for the eight patients are summarized in The mean of several determinations is shown. In patient 1, plasma PRL is also increased (67.8ng/ml). When the GH concentration exceeded 150% of the basal level at an appropriate time after a pulse, it was judged as an increase (positive response).
Hormone assays Plasma GH and the amount of GH in the effluent were determined by radioimmunoassay as reported previously (Maeda et al., 1976) . GH was kindly provided by Dr. A. Parlow (National Pituitary Agency) and Dr. H. G. Friesen (University of Manitoba, Canada).
All the samples from a given experiment were run in the same assay. Intra-and interassay coefficients of variation were both less than 10%.
Results

In vivo GH secretory dynamics
The GRF test was performed in six acromegalic patients. GRF elicited a positive response (an increase) in plasma GH in three, but a negative response in plasma GH in the other three of six patients (Table 2) . Plasma GH was increased from a basal level of 73.3ng/ml to 415.1ng/ml, from 34.4ng/ml to 193.4ng/ml and from 13.4ng/ml to 24.5ng/ml in patients 1, 2 and 8, respectively.
The CRF test was also performed in the same six patients. In patients 3 and 6, the CRF test was not performed preoperatively.
A GH increase to more than 50% over the basal was judged as a positive response,+, and that less than 50% as negative,-.();% of basal GH. CRF administration resulted in a GH increase in two patients (Table 3) . In contrast to responses to GRF, CRF elicited a smaller GH increase. Plasma GH levels changed from 46.9ng/ml to 84.8ng/ml and from 18.5ng/ml to 48.5ng/ml in patients 1 and 2, respectively, both of whom also responded to GRF.
In vitro GH secretory dynamics
In a preliminary experiment, after an equilibration period of 2h, basal GH levels were stable without marked spontaneous the end of the experiments, the addition of 50mM K+elicited a burst increase in GH in every case, indicating that the cells were viable for the period (Fig.1) . The effect of GRF on GH release in vitro was examined in all of the eight cases. The GH concentration was increased in response to GRF (100ng/ml) in seven cases ( Table 2 ). The increases were to approximately twice the basal level and peaked approximately 5min after the beginning of the pulse. GH returned to the basal level approximately 15min after the end of the pulse. GRF at a lower dose (1ng/ml) also elicited an increase in GH in the perifusate in these seven cases. A representative change in the GH concentration in response to 100ng/ml GRF is shown in Fig. 1 . The effect of CRF was examined in eight cases in vitro. A GH increase was elicited in four of eight cases in response to CRF (100ng/ml) ( Table 3 ). The magnitude and time course of the GH increase were comparable with those of GRF (Fig.  2) . Whenever an increase in GH was elicited by CRF, a GH response to GRF was also observed in vitro.
In some cases an increase in GH was elicited in vitro but not in vivo by GRF (Patients 4, 5 and 7, Table 2 ). It was probable that a GH increase to be caused by GRF was inhibited by endogenous somatostatin in vivo in these cases. Therefore, SMS 201-995 (100ng/ml) was added simultaneously with GRF (100ng/ml) to the perifusate in cases 4, 5 and 7, to evaluate the sensitivity of these adenomas to somatostatin. In these three cases, an increase in GH, which was caused by GRF alone, was abolished completely by simultaneous administration of SMS 201-995.
Further, GH was increased over the basal level 15 min after the termination of simultanous exposure to SMS 201-995 and GRF (Fig.1) .
On the other hand, an increase in GH was induced in vivo but not in vitro by CRF in patient 1 (Table 3 ). It is possible that endogenous GRF sensitized the adenoma to exogenous in vivo CRF resulting in a GH increase. Therefore, the effect of CRF (100ng/ml) in the presence of GRF administered continuously at a low dose (1 ng/ml) was examined in case 1. GRF (1 ng/ml) caused a GH increase, which peaked 15min after the beginning of the pulse and declined thereafter despite its continued presence. However, CRF added during the latter half of GRF exposure did not effect a further decline in the GH concentration (Fig.3) . In some cases (Patients 4, 5 and 7) an increase in GH due to CRF was elicited in vitro but not in vivo (Table 3 ). It was probable that endogenous somatostatin in hibited the GH response to CRF in vivo As shown above, SMS 201-995 inhibited a GRF-induced GH increase when added to the perifusate simultaneously with GRF. However, the effect of SMS 201-995 on GH secretion induced by CRF was not examined.
Discussion
In this study a bolus iv injection of GRF, unexpectedly, did not cause an increase in GH in half of the patients (three of six patients). An increase in GH either to the same or a greater extent as in the normal has been reported in the majority of acromegalics. In our patients the frequency of decreased or no response to GRF was higher than those reported previously (Wood et al., 1983 , Shibasaki et al., 1984 , von Werder et al., 1984 , Pieters et al., 1984b , Gelato et al., 1985 , Arosio et al., 1985 .
The reduced or no GH response to GRF in acromegalics could be due to a change in the hypothalamic regulatory mechanism, disappearance of GRF receptor in the pituitary, or changes in the postreceptor mechanism.
In addition, it has been reported that GH response to GRF is usually suppressed in patients with an ectopic GRFproducing tumor, a rare form of acromegaly (Schulte et al., 1985) . Although increased GH in this study was due to a pituitary adenoma in each case, excessive hypothalamic GRF might have been responsible for no or decreased GH response to exogenous GRF.
In this study GRF elicited a GH increase in vitro in seven of eight patients.
Thus, the in vivo frequency of negative GH response was much higher than that observed in vitro. This type of discrepancy might be explained by a factor(s) which interferred with GH response to GRF in vivo. First, endogenous GRF in excess might have suppressed GH response to exogenous GRF in vivo as mentioned above. However, a definite conclusion cannot be formed until the GRF in the portal system can be measured accurately. Second, endogenous somatostatin in excess might be responsible. Endogenous somatostatin might be increased as a result of feedback in a group of acromegalic patients.
In this group, an excess of endogenous somatostatin would interfere with GH response to GRF, as long as an adenoma was sensitive to somatostatin. To evaluate this possibility, an analog of somatostatin, SMS 201-995, which was demonstrated to bind specifically to somatostatin receptors in human pituitary (Reubi and Landolt, 1984) , was used in vitro in this study. An increase in GH caused by GRF (100ng/ml), was abolished completely simultaneous administration of SMS 201-995 (100ng/ml) with GRF, indicating that these adenomas were sensitive to somatostatin. However, no definite conclusion on the possible involvement of endogenous somatostatin can be drawn until the somatostatin concentration in the portal blood is measured.
In this study CRF administered iv as a bolus elicited an increase in GH in two of six acromegalics.
An increase in plasma. GH in response to CRF has been also reported in acromegalics (Pieters et al., 1984a) and in patients with primary affective disorders (Gold et al., 1983) . The frequency of a paradoxical increase in GH in response to CRF in this study was comparable to that in acromegalic reported previously (Pieters et al., 1984a) , but much lower than that caused by TRH (Faglia et al., 1973a) .
The paradoxical increase caused by CRF might also be ascribed to a change in the hypothalamic regulatory mechanism (e.g., contribution of GRF exposure to GH increase by TRH, Sartorio et al., 1986) , the aberrant appearance of receptor for CRF in somatotrophs (Pieters et al., 1984a) as postulated for the mechanism of paradoxical responses by TRH and LHRH (Faglia et al., 1973a , Faglia et al., 1973b , Matsukura et al., 1977 or changes in the postreceptor mechanism. The finding reported by Pieters et al.,(1984a) might indicate that basal GH levels determine responsiveness to CRF. In this study, basal GH was high in one and low in another responsive patient.
Taken together, these data suggest that the basal GH level is not a major determinant of GH responsiveness to CRF.
In response to CRF, an increase in GH was elicited both in vivo and in vitro in one patient proving the site of CRF action on the pituitary (Patient 2). In another patient an increase in GH was induced in vivo but not in vitro by CRF (patient 1). It was possible that endogenous GRF sensitized the adenoma to exogenous CRF in this patient as postulated for paradoxical GH response to TRH (Thorner et al., 1982 , Schulte et al., 1985 . Therefore, the effect of CRF (100ng/ml) was examined in the presence of GRF in a low dose (1ng/ml) administered continuously.
CRF, added during the latter half of GRF exposure, did not induce a GH response, though GRF (1ng/ml) alone caused a GH increase. The size of the tumor did not allow us to further examine various conditions such as the use of different doses of GRF and CRF, and timing of CRF addition. Therefore, it might be premature to draw a conclusion on the possible involvement of endogenous GRF in this patient.
The frequency of positive GH response to CRF in vitro was also higher than that observed in vivo. CRF elicited a GH increase in four of eight patients in vitro, but in only two of six patients in vivo This discrepancy might be due to the fact that endogenous somatostatin interferred with a GH increase in response to CRF in vivo as mentioned above in connection with GH response to GRF.
However, the effect of somatostatin or SMS 201-995 on the CRFinduced GH increase was not examined in these cases because of the limited size of tumor amount available.
The discrepancy between GH responses in vivo and in vitro to GRF or CRF in this study suggests that the involvement of endogenous somatostatin and/or GRF in the regulation of GH secretion in acromegalics might be qualitatively different from patient to patient.
The so-called paradoxical GH response in patients with acromegaly might reflect the secretory status of these hypothalamic hormones in vivo. In order to further verify this hypothesis it is necessary to evaluate the level of these hypothalamic hormones in the portal blood directly or indirectly.
